GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in cardiometabolic HFpEF – – Findings support further ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Lilly's drug also significantly improved heart failure symptoms and physical limitations measured using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) compared to ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...